1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

I-SPY 2 Helping To Normalize Adaptive Trial Designs

 
• By Bridget Silverman

Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.

formula

Innovations in clinical trial design like adaptive designs based on Bayesian statistics and master protocols have so far produced more enthusiasm than regulatory results, but the publication of data two cohorts from the adaptively randomized I-SPY 2 Phase II trial in the New England Journal of Medicine could go some way toward moving new designs from theory to more widespread practice.

The value of I-SPY 2, a master platform trial designed to screen multiple regimens in combination with standard neoadjuvant chemotherapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Who Does What? EU RADIAL Study Exposes Oversight Challenges In Decentralized Trials

 
• By Vibha Sharma

Decentralizing clinical research demands rethinking accountability and logistics to prevent gaps that could compromise safety and trial integrity.

France To Offer 14-Day Clinical Trial Reviews To Attract Research

 
• By Francesca Bruce

France is set to pilot a new fast-track process that could more than halve the timeline for authorizing certain clinical trial applications.

Europe’s Trials@Home Findings Show Remote Recruitment Is Complicated

 
• By Vibha Sharma

Europe’s RADIAL study comparing fully decentralized, hybrid and conventional trial approaches reveals why online recruitment is not simple.

UK Tests Standardized Site Selection Process For Streamlining Clinical Trial Setup

 
• By Vibha Sharma

Sponsors and CROs planning commercial trials in the UK can now use a standardized template to confirm NHS site selection and start study setup activities in parallel with formal contracting and regulatory approvals.

More from R&D

UK Tests Standardized Site Selection Process For Streamlining Clinical Trial Setup

 
• By Vibha Sharma

Sponsors and CROs planning commercial trials in the UK can now use a standardized template to confirm NHS site selection and start study setup activities in parallel with formal contracting and regulatory approvals.

Getting Comfortable With The Black Box: Explainable AI Techniques Build Trust

 
• By Bridget Silverman

A subfield of AI aims to explain why complex models make predictions, which will increase their interpretability and auditing ability, AI researcher Su-In Lee said during a National Academies of Sciences workshop.

Pharma Needs Incentives To Optimize Cancer Drugs, EMA Oncology Chair Says

 
• By Eliza Slawther

Incentives are “probably the only solution” to encouraging companies to optimize cancer drugs, but this will require funding and systemic changes, the chair of the European Medicines Agency’s oncology working party says.